Skip to main content
Clinical Trials/NCT01527396
NCT01527396
Completed
Not Applicable

Multi-center Prospective Observational Study for the Validation of Preoperative Low-risk Criteria for Lymph Node Metastasis in Endometrial Cancer

National Cancer Center, Korea1 site in 1 country529 target enrollmentDecember 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Endometrial Cancer
Sponsor
National Cancer Center, Korea
Enrollment
529
Locations
1
Primary Endpoint
Diagnostic odds ratio
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

The purpose of this study is to evaluate the efficacy of low risk criteria for lymph node metastasis, that was determined by KGOG-2014 retrospective study, in women with endometrial cancer.

Detailed Description

The Korean Gynecologic Oncology Group (KGOG) undertook a multi-center retrospective study to develop a preoperative prediction model for lymph node metastasis in endometrial cancer (KGOG-2014). This retrospective multi-center study showed that the accurate identification of a low-risk group for lymph node metastasis among the patients with endometrial cancer can be achieved with the new criteria using preoperative MRI and serum CA-125 assay. In this study, serum CA125 levels and three MRI parameters (deep myometrial invasion, lymph node enlargement, and extension beyond uterine corpus) were found to be independent risk factors for nodal metastasis. Based on the success of KGOG-2014, Korean Gynecologic Oncology Group initiated this prospective, multi-center observational study to validate our prior prediction model.

Registry
clinicaltrials.gov
Start Date
December 2011
End Date
August 2015
Last Updated
10 years ago
Study Type
Observational
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sokbom Kang

Director, Gynecologic Oncology Research Div.

National Cancer Center, Korea

Eligibility Criteria

Inclusion Criteria

  • Patients with a histologic diagnosis of endometrial cancer before surgical staging.
  • Patients with a preoperative magnetic resonance imaging (MRI) and serum CA-125 within 4 weeks from surgical staging.
  • Patients who underwent adequate systemic lymph node dissection during surgical staging.

Exclusion Criteria

  • Patients with a histologic feature suggesting sarcoma or squamous cell carcinoma

Outcomes

Primary Outcomes

Diagnostic odds ratio

Time Frame: 2014-12-31

Sensitivity/Specificity

Time Frame: 2014-12-31

Negative predictive value

Time Frame: 2014-12-31

Study Sites (1)

Loading locations...

Similar Trials